[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bladder-outlet-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bladder-outlet-obstruction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,83,122,152,179,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100636760","thulium-laser-enucleation-with-bladder-neck-incision-for-small-volume-benign-prostatic-hyperplasia-100636760",false,"NCT07569874","Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate Combined With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia: A Multicentre, Randomized, Single-Blind, Controlled Trial","ThuLEP-BNI","Inclusion Criteria:\n\n* Male patients aged 40-80 years.\n* Diagnosis of benign prostatic hyperplasia (BPH) and scheduled to undergo surgical treatment.\n* International Prostate Symptom Score (IPSS) of at least 12, maximum urinary flow rate of no more than 15 mL\u002Fs, with a voided volume greater than 150 mL.\n* Prostate volume of less than 30 mL measured by transrectal ultrasound (TRUS), calculated as length × width × height × 0.52.\n* Ability, as assessed by the investigator, to understand the study requirements and complete the scheduled treatment, follow-up visits, and study-related assessments.\n\nExclusion Criteria:\n\n* Inability or refusal to provide written informed consent, or inability to comply with the required follow-up schedule.\n* Prostate-specific antigen (PSA) level of 10 ng\u002FmL or higher, unless prostate cancer has been excluded by biopsy.\n* Confirmed or suspected prostate or bladder malignancy.\n* Pre-existing bladder neck contracture or urethral stricture before surgery.\n* Known coagulation disorder or abnormal coagulation function.\n* Neurogenic bladder or detrusor underactivity that may affect bladder or urethral sphincter function.\n* Benign prostatic hyperplasia (BPH) complicated by acute urinary tract infection, acute prostatitis, or bacterial prostatitis.\n* History of prostate surgery, urethral stricture, or neurogenic bladder.\n* History of prostate cancer or pelvic radiotherapy.\n* Severe cardiovascular disease, pulmonary disease, or other systemic disease that, in the investigator's judgment, would make the patient unable to tolerate surgery.\n* Participation in another clinical trial related to benign prostatic hyperplasia (BPH) within 3 months before enrolment.\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.","MALE","40 Years","80 Years",{"count":21,"type":22},615,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will evaluate the safety and effectiveness of thulium laser enucleation of the prostate combined with bladder neck incision in men with small-volume benign prostatic hyperplasia (BPH). Small-volume BPH may still cause significant bladder outlet obstruction and bothersome lower urinary tract symptoms, and the optimal surgical treatment for these patients remains uncertain.\n\nIn this multicenter, randomized, single-blind, controlled trial, 426 eligible men aged 40 to 80 years will be assigned in a 1:1:1 ratio to one of three groups: thulium laser enucleation of the prostate combined with bladder neck incision, thulium laser enucleation alone, or transurethral resection of the prostate. The main goal is to compare the incidence of bladder neck contracture at 6 months after surgery. Other outcomes include symptom improvement, urinary flow, pain score, sexual function, and safety outcomes during follow-up.",[28,29,30],"Benign Prostatic Hyperplasia","Bladder Outlet Obstruction","Lower Urinary Tract Symptoms (LUTS)",[32,33,34,35,36],"Small-Volume Benign Prostatic Hyperplasia","Thulium Laser Enucleation of the Prostate","Bladder Neck Incision","Bladder Neck Contracture","Lower Urinary Tract Symptoms","NOT_YET_RECRUITING","2026-06-16",{"date":40,"type":41},"2026-06-18","ACTUAL",{"date":43,"type":22},"2026-07",{"date":45,"type":22},"2028-06",{"name":47,"class":48},"Chinese PLA General Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":49},"100640806","a-prospective-comparative-study-evaluating-the-safety-and-efficacy-of-transurethral-thulium-fiber-laser-holmium-laser-and-bipolar-enucleation-of-large-sized-prostate-100640806","NCT07627178","A Prospective Comparative Study Evaluating the Safety and Efficacy of Transurethral Thulium Fiber Laser, Holmium Laser and Bipolar Enucleation of Large Sized Prostate","Inclusion Criteria:\n\n* Male patients diagnosed with BPH\n* Clinical diagnosis of BPH with lower urinary tract symptoms.\n* IPSS ≥ 20 (severe symptoms)\n* Maximum urinary flow rate (Qmax) ≤ 10 mL\u002Fs\n* Prostate volume \\>100 mL (measured by transrectal ultrasound)\n* Failed medical therapy and fit for operation\n\nExclusion Criteria:\n\n* Prostate cancer (current or history).\n* Previous prostate surgery\n* Previous urethral surgery.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection.\n* Severe cardiovascular disease (ASA Class IV).\n* Previous pelvic radiation.\n* Urethral stricture\n* Urinary bladder stones.",true,{"count":58,"type":22},90,[25],"This study compares the safety and efficacy of three endoscopic enucleation techniques for large prostates (\\>100 mL) in patients with benign prostatic hyperplasia (BPH): Thulium Fiber Laser Enucleation (ThuFLEP), Holmium Laser Enucleation (HoLEP), and Bipolar Enucleation (B-TUEP). Ninety male patients with severe lower urinary tract symptoms (IPSS ≥20, Qmax ≤10 mL\u002Fs) who failed medical therapy will be randomized 1:1:1 into three groups of 30. Primary outcomes include IPSS, quality of life score, maximum flow rate (Qmax), and post-void residual at 1, 3, and 6 months postoperatively. Secondary outcomes include operative time, enucleation efficiency, blood loss, catheterization duration, hospital stay, and complication rates assessed by the Clavien-Dindo classification.",[62,63,29],"Benign Prostatic Hyperplasia (BPH)","Lower Urinary Tract Symptom",[65,66,67,68,69,70,71,72],"Prostate Enucleation","ThuLEP","HOLEP","Bi-TUEP","TFL","BPH Surgery","IPSS","Uroflowmetry","RECRUITING","2026-06-03",{"date":76,"type":41},"2026-06-05",{"date":78,"type":41},"2025-10-21",{"date":80,"type":22},"2027-05-30",{"name":82,"class":48},"Tanta University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":96,"conditions":97,"keywords":106,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100410565","early-phase-1-concomitant-renal-and-urinary-bladder-allograft-transplantation-100410565","NCT04626167","Concomitant Renal and Urinary Bladder Allograft Transplantation","Inclusion Criteria:\n\n* Male or female patients between 1 yr. and 60 years of age.\n* Subject is willing and able to give signed informed consent, or have a legally authorized representative who is willing and able to give consent. Informed assent will be required for children 6-17 years of age as appropriate or warranted.\n* Patients with CKD secondary to neurogenic bladder, lower urinary tract obstruction or other disorders of the urinary bladder.\n* Medical need for a bladder transplant, as defined by the presence of exhibiting \"hostile bladders\" defined as end filling pressure or detrusor leak point pressure (DLPP) of or greater than 40 cm H20 or at below estimated bladder capacity for age, or detrusor overactivity with detrusor sphincter dyssynergia, or new onset of upper urinary tract changes (hydronephrosis, vesicoureteral reflux) in the last 12 months\n* If a concomitant kidney transplant is being considered, additionally, estimated GFR less than or equal to 20 mL\u002Fmin or dialysis. If GFR 20-25 mL\u002Fmin would also qualify if expected progression is rapid (\\>10 mL\u002Fmin\u002Fyear)\n* Vetting and approval by the Mayo Clinic multidisciplinary transplant team (MDC) for renal transplantation.\n* Ability of subject and\u002For care provider to be successfully trained in clean intermittent catheterization and bladder cycling. Or current use of CIC.\n* Utilization of maximally-tolerated dose and regimen of medical therapy (e.g. anticholinergics) or failure to tolerate\u002Fcontraindications to such agents.\n* Psychosocial clearance: Demonstrated commitment to psychological evaluation perioperatively, in which the psychologist must confirm that the subject has the maturity and stable psychosocial environment necessary for this research study.\n* Agree to avoid pregnancy for 1 year after surgery through abstinence or approved contraception as noted in Appendix A (female subjects only)\n* If patient has a history of malignancy (with the exception of localized non-melanoma skin cancer) the patient must be at least 5 years from termination of treatment without evidence of recurrent disease.\n\nExclusion Criteria:\n\n* They are pregnant or breastfeeding, or planning a pregnancy during the course of the study, or who are of child bearing potential and not willing to continue using an effective method of birth control (i.e. with a low failure rate of less than 1 percent per year including injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or a vasectomized partner), or\n* Any contraindication to general anesthesia or evaluation reveals that the subject cannot safely undergo general anesthesia and post-operative recovery due to severe cardiovascular, pulmonary, neurological, metabolic, or rheumatologic disease (requires special consultation)\n* Any contraindication or known anaphylactic or severe systemic reaction to either human blood products or materials of bovine origin\n* Subjects with a current positive (\\>=5 mm induration for high-risk subjects; otherwise \\>=10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n* Known history of hypersensitivity to aminoglycosides or fluoroquinolones\n* Use of any investigational product within 3 months\n* Prior participation in the study\n* Currently smoking\n* Current incarceration for any reason\n* Unwillingness, inability, or unlikely compliance of individual and\u002For primary caregiver with study related schedules procedures, management, or follow -up in the opinion of the PI and\u002For co-investigators\n* Any circumstance in which the investigator deems participation in the study is not in the subject's best interest\n* Subjects with an ALT or AST value \\>3 times the upper limit of normal\n* Subjects with acute or chronic abdominal skin infections and\u002For acute or chronic abdominal inflammatory conditions such as inflammatory bowel disease\n* Subjects with uncontrolled diabetes defined as HgA1c\\>10, unstable cardiac and\u002For pulmonary disorders, or bleeding disorders\n* Active malignant neoplasm (with the exception of localized non-melanoma skin cancer) that is untreated, unresponsive to available treatment, or too recently treated to determine relapse risk.\n* Surgical procedure for transplantation cannot be successfully performed for anatomical reasons\n* Life expectancy with successful transplantation is estimated to be \\\u003C5 years for any reason.\n* There is any other disease, physical examination finding, or clinical laboratory result that provides a reasonable suspicion of a disease or condition that contraindicates the procedure or the interpretation of results or render the subject at high risk for treatment complications, or\n* Serious or uncontrolled psychiatric illness or disorder that could compromise their understanding of, or compliance with, follow-up visits\u002Fcare after transplant, or\n* Taking medications on specified hourly intervals that may be affected by changes to renal clearance, or\n* Hypertension stage II \\> 99th percentile, unless they had a complete workup to exclude secondary etiologies other than being overweight, or\n* Presence of severe coagulopathy, (hyper or hypo)\n* Patient is not up to date on current CDC recommended vaccines","ALL","1 Year","60 Years",{"count":93,"type":22},30,[95],"EARLY_PHASE1","The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.",[98,99,100,101,102,103,29,104,105],"Chronic Kidney Diseases","Bladder Dysfunction","Bladder Absence","Posterior Urethral Valve","Neurogenic Bladder","Bladder Exstrophy","Failure, Kidney","Transplant",[107,108,109,110,111],"Urinary Bladder Transplant","Bladder Transplant","Bladder Augment","Neobladder","Ileocystoplasty","2026-04-20",{"date":114,"type":41},"2026-04-23",{"date":116,"type":41},"2021-06-01",{"date":118,"type":22},"2026-08",{"name":120,"class":48},"Mayo Clinic",2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":19,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":49},"100607871","high-intensity-focused-ultrasound-hifu-ablation-for-treatment-of-prostate-tissue-in-bladder-outlet-obstruction-100607871","NCT07194187","High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction","HIFU for BOO","Inclusion Criteria:\n\n* Males aged 45 - 80 diagnosed with LUTS due to BOO from BPH.\n* Prostate size \\> 30cc and \\\u003C 80cc as measured by transrectal ultrasound (TRUS) or MRI within 1 year prior to treatment.\n* A documented history of refusal to take medical therapy, inadequate or failed response to medical therapy, or contraindications to medical therapy.\n* Initial baseline International Prostate Symptom Score (IPSS) greater than or equal to 12 which denotes moderate to severe symptoms.\n* Baseline peak urinary flow rate (Qmax) of less than 15 mL\u002Fs1\n* Baseline serum creatinine \\\u003C 2 mg\u002FdL within 30 days prior to surgery\n* Mental capacity, willingness, and ability to sign a study specific informed consent form\n\nExclusion Criteria :\n\n* BMI \\> 42\n* Patients with an obstructing prostatic median lobe as measured by baseline preliminary imaging and\u002For confirmed on cystoscopy examination.\n* Patients with latex allergies which would permit latex catheterization perioperatively as silicone catheterization is not recommended during HIFU treatment.\n* Patients with extensive calcification in the treatment area of the prostate as measured by preoperative imaging with TRUS or MRI and as evaluated by hospital radiology or the principal investigator. Extensive calcification is defined as where the calcification in posterior peripheral zone, which may interfere with experimental treatment procedure, and it is determined by hospital radiologist and further assessed by the PI.\n* Patient unable to stop anticoagulants, antiplatelet agents, or NSAIDS (including aspirin \\> 100mg) prior to treatment which is standard of care.\n* Patients using immunosuppressants including corticosteroids (except inhalants) who are unable to withhold medications prior to treatment which is standard of care.\n* Known and documented coagulopathy or platelet disorder\n* Contraindication to both general and spinal anesthesia which are standard of care.\n* Severe illness that would prevent complete study participation.\n* History of active or prior treatments for current\u002Fsuspected PCa.\n* Diagnosis of polyneuropathy\n* Bladder calculi or bladder diverticulum (pouch size \\> 20% of full bladder size)\n* Active infection, including urinary tract infection or prostatitis.\n* Evidence of hydronephrosis on imaging.\n* Pre-op urinary catheter uses daily.\n* Previous urinary tract surgeries such as, but not limited to prior surgery for LUTS, urinary diversion, artificial urinary sphincter, or penile prosthesis.\n* Diagnosis of clinically significant urethral stricture, meatal stenosis, severe phimosis, or bladder neck contracture\n* Known damage to the external urinary sphincter.\n* Open heart surgery or cardiac arrest \\\u003C 180 days prior to the date of informed consent\n* Known illicit substance abuse.\n* Use of anticholinergics (specifically for bladder problems). Use of general anticholinergics is allowed if they do not have documented adverse urinary side effects.\n* Dementia or psychiatric conditions which prevent them from completing the required follow up.\n* Prior pelvic radiotherapy\n* Participation in another ongoing investigational study that could affect responses.\n* Unwillingness to accept a transfusion should it be required.\n* No members of vulnerable populations will be included in our study.\n* History or current diagnosis of chronic prostatitis.\n* Diagnosis or prior treatment for chronic pelvic pain syndrome.","45 Years",{"count":131,"type":22},17,[25],"Objectives: To assess the efficacy of HIFU therapy for benign prostatic tissue ablation in patients with lower urinary tract symptoms (LUTS) due to bladder outlet obstruction (BOO) that caused by Benign prostatic hyperplasia (BPH).\n\nThe primary objective of the study is to determine the efficacy of HIFU therapy by assessing the changes in IPSS score in 6-month post HIFU procedure for BPH with compared to baseline.\n\nThe secondary objectives of this study are as follow:\n\n* To assess any adverse events related to the procedure or device.\n* To assess the operation related characteristics including: total operation time and ablation time required in HIFU procedure for BPH, total catheterization time after the HIFU procedure for BPH, and categorical ablation zone\n* To assess the patient's post operative pain level at different post op time points.\n* To assess the urinary flow and symptoms improvement by studying the changes in IPSS, Qmax, and PVR at different post op time points compared to the baseline.\n* To assess the effectiveness of HIFU by studying the changes in PSA levels, types of medication for BPH or any urologic condition, proportion of patients who are taking BPH medication, prostate volume, and prostate calcification level and the reoperation rate within 12-month post-op.\n* To assess changes in patients' sexual function at different post op time points.\n\nThe hypothesis is that a HIFU ablation is a safe and effective treatment for patients with LUTS due to BOO from BPH.",[29,135],"BPH",[137,138,139,140,141,142],"High-intensity focused ultrasound","Interventional","Single Arm","benign prostatic hyperplasia treatment","International Prostate Symptom Score","Device Safety","2026-04-03",{"date":145,"type":41},"2026-04-09",{"date":147,"type":22},"2026-06-01",{"date":149,"type":22},"2027-09-20",{"name":151,"class":48},"Icahn School of Medicine at Mount Sinai",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":160,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":121},"100307401","fetal-cystoscopy-for-severe-lower-urinary-tract-obstruction-100307401","NCT03281798","Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction","Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO): A Prospective Trial","CYSTO","Inclusion Criteria:\n\n1. Pregnant women\n2. Singleton pregnancy\n3. Maternal age ≥ 18 years\n4. Male fetus with LUTO, dilated bladder, \"keyhole sign\" and bilateral hydronephrosis\n5. Oligohydramnios or Anhydramnios\n6. Favorable urine analysis defined as urinary sodium is \\\u003C 100 milliequivalents per liter (mEq\u002FL), chloride \\\u003C 90 mEq\u002FL, and osmolality \\\u003C 200 milliosmoles per kilogram (mOsm\u002Fkg) after 20 weeks and in the absence of previous in utero intervention for the disease (vesicoamniotic shunt placement or fetal cystoscopy).\n7. Absence of chromosomal abnormalities and associated anomalies\n8. Gestational age at the time of the procedure will be between 16 0\u002F7 weeks and 25 6\u002F7 weeks\n9. Normal karyotype by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). Patients declining invasive testing will be excluded.\n10. Family have considered and declined the option of termination of the pregnancy at less than 24 weeks.\n11. Family meets psychosocial criteria, including sufficient social support and ability to understand requirements of the study.\n12. Parents or guardian are willing to provide signed informed consent.\n\nExclusion Criteria:\n\n1. Fetal anomaly unrelated to LUTO\n2. Congenital cardiac anomaly\n3. Female fetus\n4. Increased risk for preterm labor including short cervical length (\\\u003C1.5 cm), history of incompetent cervix with or without cerclage, and previous preterm birth\n5. Placental abnormalities (previa, abruption, accreta) known at time of enrollment\n6. Contraindications to surgery including previous hysterotomy in active uterine segment\n7. Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal membrane separation, uterine anomalies incompatible with fetoscopy\n8. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy\n9. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment\n10. Maternal medical condition that is a contraindication to surgery or anesthesia\n11. Patient does not have health insurance to cover routine clinical care including prenatal care, prenatal ultrasound, amniocentesis, tocolysis, admission, delivery, and fetal vesico-amniotic shunting. The exception will be fetal cystoscopy which is considered an experimental procedure.\n12. Inability to comply with travel and follow-up requirements of the trial\n13. Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy\n14. Patients declining invasive testing\n15. Family does not meet psychosocial criteria including insufficient","FEMALE","18 Years",{"count":163,"type":22},10,[25],"The purpose of the study is to study the outcomes of maternal and fetal patients who are undergoing fetal intervention for severe isolated lower urinary tract obstruction (LUTO).",[167,168,29,169],"Lower Urinary Tract Obstructive Syndrome","Lower Urinary Tract Obstruction, Congenital","Bladder Outflow Obstruction","2026-02-20",{"date":172,"type":41},"2026-02-24",{"date":174,"type":41},"2018-01-01",{"date":176,"type":22},"2028-08-01",{"name":178,"class":48},"Rodrigo Ruano",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":197,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":49},"100626004","predictors-of-trifecta-achievement-after-holep-100626004","NCT07429994","Predictors of Trifecta Achievement After HoLEP","Predictors of Trifecta Achievement After Holmium Laser Enucleation of the Prostate","ReMIUS-BPO","Inclusion Criteria:\n\n* All male patients aged ≥ 40 years who are candidates for surgical treatment for BPO.\n* Ability to provide informed consent, when required.\n\nExclusion Criteria:\n\n* Clinically proven active condition(s) that require another intervention other than BPO surgery, such as lower urinary tract malignancy, urethral stricture, or neurogenic lower urinary tract symptoms.\n* History of previous surgery for BPO, urethral stricture, or prostate cancer.\n* Incomplete baseline or procedural data.",{"count":188,"type":22},604,[25],"Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment option for men experiencing bothersome lower urinary tract symptoms due to an enlarged prostate. Researchers predict that specific participant or operator-dependent conditions before or during HoLEP may influence the trifecta outcome, based on similar studies. Therefore, the aim of this study is to understand what these conditions are. Trifecta success indicates a high-quality surgery based on three essential criteria: the treatment's effectiveness, ease of recovery, and the absence of serious side effects. In this study, trifecta is defined as relief from bothersome symptoms validated by international symptom score questionnaires, no urinary incontinence, and no serious events occurring within three months after HoLEP.",[192,193,194,195,30,196,29],"HoLEP","Trifecta Achievement","Urinary Incontinence Following Surgical Procedure","Clavien Dindo Surgical Complication Scale","Benign Prostatic Enlargement (BPE)",[198,199,200],"HoLEP Trifecta","HoLEP Symptomatic Relief","HoLEP Predictive Factors","2026-02-18",{"date":172,"type":41},{"date":204,"type":22},"2026-01-30",{"date":206,"type":22},"2028-07-31",{"name":208,"class":48},"Ondokuz Mayıs University",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100625003","urinary-ctgf-in-benign-prostatic-obstruction-100625003","NCT07416981","Urinary CTGF in Benign Prostatic Obstruction","The Relationship of Urinary CTGF Levels With Bladder Fibrosis and Surgical Treatment Response in Patients With Benign Prostatic Obstruction","Inclusion Criteria:\n\nMale patients aged \\> 40 years\n\n* Diagnosis of benign prostatic obstruction (BPO), with or without an indwelling catheter\n* Patients with an indication for surgical treatment according to EAU guidelines\n\nExclusion Criteria:\n\n* Age \\\u003C 40 years\n* Female sex\n* Prostate-specific antigen (PSA) \\> 2.5 ng\u002FmL\n* History of endoscopic urological intervention\n* Previous urogenital malignancy or urological surgery\n* Diabetes mellitus\n* Urethral stricture\n* History of pelvic radiotherapy and\u002For chemotherapy\n* Patients performing clean intermittent catheterization\n* Neurological diseases causing secondary urinary symptoms (e.g., spinal cord injury, stroke, multiple sclerosis, Parkinson's disease)\n* History of spinal surgery\n* History of colorectal cancer or previous colorectal surgery",{"count":217,"type":22},50,"OBSERVATIONAL","Benign prostatic obstruction (BPO) is one of the most common causes of bladder outlet obstruction (BOO) and may lead to progressive structural and functional alterations in the bladder over time. Prolonged obstruction triggers a bladder remodeling process characterized by detrusor hypertrophy, ischemia-reperfusion injury, smooth muscle loss, and progressive fibrosis. These pathological changes may result in impaired detrusor contractility, increased post-void residual volume, and suboptimal functional recovery following surgical treatment.\n\nConnective tissue growth factor (CTGF) is a matricellular protein that plays a key role in fibrogenesis and is markedly upregulated under hypoxic, ischemia-reperfusion, and inflammatory conditions. Experimental and cellular studies have demonstrated that CTGF promotes fibroblast proliferation, extracellular matrix production, and collagen deposition, thereby contributing to bladder fibrosis. Increased CTGF expression has also been associated with fibrotic differentiation of bladder smooth muscle cells.\n\nThe aim of this observational study is to evaluate the relationship between urinary CTGF levels, bladder fibrosis, and functional response to surgical treatment in patients with benign prostatic obstruction. Preoperative urinary CTGF levels will be assessed and correlated with postoperative functional outcomes and clinical improvement. This study aims to determine whether urinary CTGF may serve as a non-invasive biomarker of bladder fibrosis and a potential predictor of surgical treatment response in patients with BPO.",[28,29,63],"2026-02-10",{"date":201,"type":41},{"date":224,"type":22},"2026-04-01",{"date":226,"type":22},"2026-12-01",{"name":228,"class":48},"Tarik Emre Sener"]